target upgrad unit state go sg websit
merck co inc
upsid tp
us favourit compound three reason expect
immunotherapi io drive meaning upsid surpris forecast
rich sustain cash return sharehold view
valuat alreadi discount modest patent driven declin ep
perceiv lack growth driver outsid io note
manag foremost strateg prioriti next decad
deliv sustain top- bottom-lin growth dont share
broadli held concern acquisit risk view organ
solut like breadth compani
 activ expect pipelin low
nc chang
chang ep forecast increas better sale
outsid immunotherapi us tax reform off-set bit less margin expans new
ep estim ahead consensu still believ investor
underestim potenti immunotherapi therapeut geograph
valuat usual tp base straight averag ev/ebita
multipl dcf increas tp reflect
estim chang target price-to-earnings impli multipl expans
premium global pharma univers captur upsid risk consensu
ep forecast estim dividend/shar forecast tsr
risk acknowledg full result high profil phase immunotherapi
keynot studi treatment lung cancer patient still publish howev
expect result clinic meaning trial hit co-
primari endpoint earli interim analysi keytruda estim
consensu continu assum share segment
io market account mrk first-mov advantag simplic
keytruda regimen howev also note everi five point share loss
keytruda treatment naiv lung cancer would drive downsid group
ebit estim meanwhil poor execut biosimilar would drive low single-digit
downsid ebit estim although cultur highli unlik think
transform acquisit would like drive dividend cut
societ general sg seek busi compani cover research report result investor awar
sg may conflict interest could affect object report investor consid report singl factor
make invest decis pleas appendix end report analyst certif
merck co inc
merck co known merck sharp dohm msd outsid us origin
establish us subsidiari german compani merck kgaa merck co
import medium-term growth driver immunotherapi io cancer drug keytruda
enter portfolio via acquisit schere plough us
market lead franchis vaccin anim health ceo ken frazier mandat
retir end md roger perlmutt phd perceiv play critic
role reviv us sinc rejoin compani although
doesnt mandatori retir age dr perlmutt
product relev invest debat
acquisit schere plough
like mani competitor suffer deflat us
vaccin
global allianc astrazeneca book product sale
nr vaccin industri oligopoli enjoy high barrier
invest debat
reason
reason
market leader immunotherapi potenti market
medium-term growth highli depend keytruda
immunotherapi drive above-averag growth posit surpris
unclear succeed ceo head
attract valuat cash return sharehold
immunotherapi leadership threat
merck co inc
chang estim
group sale chang sg estim comparison consensu
increas ep forecast better sale outsid immunotherapi
us tax reform off-set bit less margin expans new ep estim
ahead consensu still believ investor underestim potenti
immunotherapi therapeut geograph
non-gaap/cor ep chang sg estim comparison consensu
sg cross asset research/equ note sector compris sg global coverag
sg cross asset research/equ note sector compris sg global coverag
merck co inc
use cash
although merck co offer solid ep growth prospect believ also attract
stori incom investor estim compani gener annual post-tax free
cash flow excess around return sharehold via
dividend buyback also expect us bolster organ extern
collabor compani openli acknowledg much best scienc
take place outsid lab howev think far like compani
nich bolt-on acquisit transform deal
rather provid exhaust list tabl describ key needle-mov
event stock next three year view import mileston
period releas phase data treatment naiv first line lung
cancer trial uss immunotherapi keytruda tabl
merck co inc
us price-to-earnings rel world pharma
sg cross asset research/equ note sector compos
shown chart left stock rerat recent due better
execut immunotherapi howev us roll one-year forward price-to-earnings sinc
volatil uncertainti time read-out high profil keynot
trial believ might sever weaken compani posit
potenti market treatment naiv patient stage iv lung cancer investor feedback also
suggest multipl suppress percept keytruda
compani materi growth driver
sg cross asset research/equ note sector compos
usual tp base straight averag ev/ebita multipl
dcf rais tp reflect estim chang target
merck co inc
price-to-earnings impli multipl expans premium global pharma
univers captur upsid risk consensu ep forecast next tabl
still assum wacc perpetu growth rate
tabl model impact central scenario positive/mor
neg take relev product current portfolio late-stag
pipelin help us calibr magnitud risk compani face go
forward use ebit analysi given long product cycl
pharmaceut industri us forecast upsid risk ebit
estim downsid ie vs
sale varianc sourc upsid downsid ebit varianc sourc upsid downsid
merck co inc
merck co inc
product sold
net earn sharehold
equival
total liabil equiti
chang work capit
flow oper activ
purchas secur net
flow invest activ
net chang debt
proce issue/buyback share
flow financ activ
effect foreign exchang
net chang cash/cash equival
begin year
end year
sg cross asset research/equ balanc cash flow estim number
merck co inc
merck co bull/bear scenario potenti impact ebit
sale
impact
impact
franchis grow
sale declin patent expiri
drug approv new indic
sale doubl sandoz target
sale one quarter sandoz target
full approv indic current phase
full approv indic current phase
merck co inc
merck co inc
share basic year end/outstand
share price average hist yr current
valu minor
valu financi invest
depreci amortis
chang work capit
flow oper activ
flow invest activ
flow financ activ
net chang cash result cf
intang
merck co inc
report complet cet
merck co inc us buy
follow name research analyst herebi certifi certifi view express research report accur reflect
person view subject secur issuer ii part compens
relat directli indirectli specif recommend view express report justin smith
analyst author research employ sg affili locat includ limit pari london new york
hong kong tokyo bangalor frankfurt madrid milan seoul warsaw
histor price merck co inc mrk
valuat methodolog merck co inc
tp straight averag sotp base averag ev/ebita multipl dcf wacc termin growth
downsid risk keytruda estim consensu assum market share highest-profil form lung
cancer account first-mov advantag simplic keytruda regimen everi share loss would
result downsid group ebit estim meanwhil poor execut biosimilar would result low-single-digit
downsid ebit estim although transform acquisit cultur highli unlik think acquisit
would like lead dividend cut
merck co inc
sg equiti research rate month period
buy absolut total sharehold return forecast
month period
equiti rate dispers relationship
hold absolut total sharehold return forecast
month period
sell absolut total sharehold return forecast
plu forecast cash dividend incom includ incom
special dividend paid month period rate
determin rang describ time
initi coverag chang rate subject limit
manag discret time rate may fall outsid
rang market price movement and/or
short term volatil trade pattern interim deviat
specifi rang permit becom subject
review research manag
sector weight definit month period
sector weight assign sg equiti research
strategist distinct separ sg equiti research
analyst rate base relev
overweight sector expect outperform relev broad
market benchmark next month
neutral sector expect perform in-lin relev
broad market benchmark next month
underweight sector expect under-perform relev
broad market benchmark next month
prefer least prefer stock select
cover analyst base individu analyst coverag
univers sg equiti research strategist
price inform includ report market close unless otherwis state
disclaim sourc inform exclus properti morgan stanley capit intern inc without
prior written permiss inform intellectu properti may reproduc redissemin
use creat financi product includ indic inform provid basi user assum entir
risk use made inform affili third parti involv relat comput compil
inform herebi expressli disclaim warranti origin accuraci complet merchant fit particular
purpos respect inform without limit forego event shall affili
third parti involv relat comput compil inform liabil damag kind morgan
stanley capit intern index servic mark affili similar languag may
provid approv advanc
sg act co-manag novarti financ sa bond issu senior
sg act co-manag novarti financ bond
